Germline mutations in genes encoding subunits of succinate dehydrogenase (SDH) are associated with hereditary paraganglioma and pheochromocytoma. Although most mutations in SDHB, SDHC and SDHD are intraexonic variants, large germline deletions may represent up to 10% of all variants but are rarely characterized at the DNA sequence level. Additional phenotypic effects resulting from deletions that affect neighboring genes are also not understood. We performed multiplex ligation-dependent probe amplification, followed by a simple long-range PCR 'chromosome walking' protocol to characterize breakpoints in 20 SDHx-linked paraganglioma-pheochromocytoma patients. Breakpoints were confirmed by conventional PCR and Sanger sequencing. Heterozygous germline deletions of up to 104 kb in size were identified in SDHB, SDHC, SDHD and flanking genes in 20 paraganglioma-pheochromocytoma patients. The exact breakpoint could be determined in 16 paragangliomapheochromocytoma patients of which 15 were novel deletions. In six patients proximal genes were also deleted, including PADI2, MFAP2, ATP13A2 (PARK9), CFAP126, TIMM8B and C11orf57. These genes were either partially or completely deleted, but did not modify the phenotype. This study increases the number of known SDHx deletions by over 50% and demonstrates that a significant proportion of large gene deletions can be resolved at the nucleotide level using a simple and rapid method.
with the development of familial PGL/PCC. SDH plays a central role in the tricarboxylic acid cycle, converting succinate to fumarate, while providing electrons for oxidative phosphorylation via the inner mitochondrial membrane. Despite the close functional relationship of the SDH proteins, mutations of subunit genes lead to clear differences in clinical phenotype. While SDHD and SDHAF2 mutations predominantly result in head and neck PGLs, SDHB mutations are more closely associated with extra-adrenal PGL and metastatic disease (8, 9) . SDHA and SDHC mutations are very rare and are currently associated with both PGL and PCC (10, 11) .
A wide variety of SDH gene mutations have been described and listed in the SDH mutation database at http://chromium.liacs.nl/LOVD2/SDH/home.php (12) , and over 400 variants are now included. The majority of mutations in the SDH genes are point mutations and small deletions, which are easily detected by direct sequencing. Large deletions are rarely detectable using this method, but the widespread adoption of multiplex ligation-dependent probe amplification (MLPA), and other methods has led to the identification of many large deletions (13) (14) (15) (16) . The SDH mutation database currently contains 31 large deletions, including some relatively common variants such as the SDHB Dutch founder deletion in exon 3 (17, 18) . However, few deletions have been fully characterized and it is not known whether partial or complete deletion of additional genes has any phenotypic effect. In addition, mechanisms underlying deletion such as Alu repeat-mediated recombination, which is known to play a major role in germline deletions affecting VHL (19) , have not yet been extensively explored in the SDH genes.
We collected samples from PGL/PCC patients who tested negative for point mutations by Sanger sequencing of the SDH genes. MLPA gene deletion analyses of SDHB, SDHC and SDHD in these patients led to the identification of 20 SDH-related gene deletions. The exact breakpoint could be determined in 16 PGL/PCC patients and the majority of these deletions were rapidly identified using a simple 'chromosome walking' long-range PCR method. Of the 15 novel deletions identified, six also affected neighboring genes. This study illustrates the ease-of-use of this long-range PCR method and suggests that it may be the most rapid and practical approach for further characterization of single or small number of deletions. However, this study also illustrates the drawbacks of this method in the analysis of complex or very large deletions (>100 kb).
Material and methods

Patients
DNA samples from 20 index paraganglioma/pheochromocytoma patients were obtained from the AlbertLudwigs University, Freiburg. Genomic DNA was extracted using standard methods from EDTA-anticoagulated blood samples. Following initial Sanger sequencing and MLPA analysis at AlbertLudwigs University, the samples were further analyzed at the Department of Human Genetics, Leiden University Medical Center. Informed consent was obtained for DNA testing according to protocols approved by ethics committee of the Albert-Ludwigs University, Freiburg. Clinical and genetic data for tumors included in the study are provided in Table S1 (Supporting information). All included patients were found to be negative for pathogenic mutations by sequencing.
MLPA
Screening for large deletions was carried out using the P226-B1 MLPA kit, following the manufacturer's protocol (MRC-Holland, Amsterdam, The Netherlands). This P226-B1 probemix contains probes for all exons of the SDHB, SDHC and SDHD genes. In addition, 10 reference probes are included in this probemix, detecting 10 different autosomal chromosomal locations.
Long-range PCR
Long-range PCR was carried out using the Takara LA Taq kit (Takara Bio Inc., Lucron Bioproducts, B.V., Gennep, The Netherlands) according to manufacturer's recommendations, except that the final volume was reduced to 20 μl. Approximately 30 ng of genomic DNA isolated from whole blood was used per reaction. The long-range PCR protocol was as follows: first an initial melting phase at 95 ∘ C for 3 min, followed by 35 cycles of 30 s at 95 ∘ C, 15 min at 68 ∘ C (20 min for fragments over 10 kb), and finally an extension phase for 10 min at 72 ∘ C. Primers were designed using the Primer3 program (http://frodo.wi.mit.edu/), with a left or right primer specified and subsequent primers selected using standard parameters (loosened when no primer was found). The primers used to determine the breakpoints of the 16 deletions identified in the SDH genes are described in Table  S2 . DNA sequences were downloaded from the UCSC genome browser using the pages gene sorter, genomic sequence, and get genomic sequence near gene, with the extent of appropriate upstream or downstream sequences specified, together with repeat masking. Primer3 allows the analysis of up to 200 kb of genomic sequence, so all primers required for a particular deletion analysis strategy were designed together. Alu sequences were analyzed using Repbase (Jurka, 2000) (http://www.girinst. org/repbase/index.html). PCR fragments spanning a deletion were characterized in detail by Sanger sequencing. Results from the sequenced PCR products were analyzed using either the Multalin program (http://multalin. toulouse.inra.fr/multalin/multalin.html) or the Blat program https://genome.ucsc.edu/cgi-bin/hgBlat. Deletion nomenclature follows HGVS guidelines.
Quantitative PCR
Broad mapping of the selected deletions was carried out by quantitative PCR of DNA using the iQ SYBR Green Supermix (Bio-Rad, CA) on a CFX96 Real-Time System (Bio-Rad). Bio-Rad CFX Manager 3.0 software was used to analyze the data. Primers were designed using Primer3 software on repeat masked sequences (primer sequences available upon request). PCR reactions and quantification of PCR products were performed as previously described (20, 21) . All measurements were carried out in triplicate. Ratios of 0.85-1.25 were accepted as diploid, while values of 0.35-0.70 were considered to be haploid, as described previously (19) .
Results
MLPA analysis
MLPA analysis, which is based on the quantification of multiplexed amplified DNA fragments, allows the identification of large deletions. MLPA screening identified 10 cases with partial or complete germline deletions of SDHB, 4 cases with deletions of SDHC and 6 cases with deletions of SDHD ( Table 1) . Patients with SDHB deletions showed a variety of deletions in the proximal part of the gene including the SDHB promoter, exons 1 and 2 (patients 1, 2, 3 and 6), complete gene deletions (patients 4 and 5), and deletions affecting distal exons (patients 8, 9 and 10). A previously described Dutch founder deletion affecting exon 3 of the SDHB gene was identified in one patient (patient 7) (17) .
Of the four patients with SDHC-related deletions, three had deletions that extended beyond the boundaries of the gene, including two patients with deletions in exons 4, 5 and 6 (patients 11 and 12), and patient 14 with a deletion of exons 5 and 6 (Table 1 ). Only patient 13 showed a deletion confined to the internal exons 3 and 4.
Of the six patients with deletions in SDHD, five had deletions that affected extragenic regions, including distal deletions affecting exons 3 and 4 (patient 15 and 20) , deletions of the SDHD promoter and proximal exons (patients 16 and 17) and a complete gene deletion (patient 18). One patient appeared to have an internal deletion confined to exon 3 of SDHD (patient 19).
Long-range 'chromosome walking' PCR
We used long-range PCR to refine deleted regions and, in some cases, to immediately identify exact breakpoints. Long-range PCR is conventionally used as a secondary method to narrow regions around deletions that have been located approximately by other methods such as qPCR or microsatellite mapping. In a previous publication we briefly described exclusive use of long-range PCR in the rapid mapping of the breakpoints of four SDH gene deletions (13) . Here we wished to further explore the practicality of using this approach as a primary method of breakpoint identification. Forward or reverse primers were designed in undeleted regions of the SDH genes when known, with strategies for individual deletions developed based on the known location of deleted and retained regions as defined by MLPA. For example, in the case of a proximal deletion extending for an unknown distance upstream of a gene, several reverse primers are designed in a retained exon and into the possibly retained proximal intron region (Fig. 1a) . Forward primers are concurrently designed at increasing distances beyond the region known to be deleted, with steps of around 5 kb, depending on the location of masked repeat regions in the gene sequence. Following long-range PCR, amplified products are analyzed by gel electrophoresis and compared to theoretical products from the wild type allele and possible deletion alleles. The staggered design of primers pairs (R1 + F1, R1 + F2, R1 + F3, etc.) will in some cases produce a ladder effect on an agarose gel that immediately suggests the presence of a deletion. In other cases, a single dominant product of the correct size will suggest a specific PCR product. Suspected positive PCR products must be confirmed by Sanger sequencing (Fig. 1b) . The breakpoint can then be directly sequenced from such deletion junction-containing fragments or further refined by conventional PCR and sequencing. Thirteen of 20 deletions were rapidly identified using this 'chromosome walking' long-range PCR approach. Ranging from 2.5 kb up to 44 kb, 10 deletions included extragenic regions. A total of 288 PCR reactions were required to identify the breakpoints of 13 deletions, representing an average of 22 PCR reactions per deletion. Even using the relatively basic and low-throughput approach of 96-well PCR followed by gel electrophoresis, little more than three PCR plates were required to identify these deletion breakpoints. In some cases where products were too large for convenient sequencing across a breakpoint or mononucleotide repeats hindered sequencing, additional primers were designed to simplify Sanger sequencing.
By contrast, an additional 629 PCR reactions failed to identify the seven unresolved deletion breakpoints (approximately 90 per deletion). Deletions encompassing an entire gene were particularly problematic, because (B)   F1  F2  F3  F4  F5  F6  F7   R1  R2  R3  R4  R5   110 100 90  80  70  60  50  40  30 in the absence of an anchoring gene sequence the number of forward and reverse primer combinations expands rapidly and results in significant numbers of false positive PCR products that have to be further analyzed. Extended analysis can also lead to the depletion of DNA samples that are only available in limited quantities.
Mapping of deletions by qPCR
The seven deletions (patients 1, 4, 5, 13, 14, 15, 18) that could not be resolved by long-range PCR analyses were subjected to broad mapping by SYBR Green qPCR (20) .
Primers were designed to amplify 100-300 bp DNA fragments of the genomic sequence of the SDHB, SDHC and SDHD genes, using steps of around 8 kb between primer sets and including 100 kb upstream and 100 kb downstream of the coding regions where appropriate. Amplicons of patient DNA with an unresolved deletion were compared to amplicons derived from DNA lacking an SDH gene deletion. Relative ratios of 0.85-1.25 were considered to be diploid, while values of 0.35-0.70 were taken as indicators of a haploid genome region. The deletion breakpoint for patient 1 (deletion of SDHB promoter and exon 1) was narrowed by qPCR (a) analysis to a region 44 kb upstream of SDHB (Fig. 2a) . The breakpoints for patient 4 were mapped to regions 21 kb upstream and 95 kb downstream of SDHB. However, downstream qPCR results were variable, with ratios of 0.70-0.90 in the region 96 kb to 165 kb of SDHB. Breakpoints for patient 5 were mapped to areas 76 kb upstream and 28 kb downstream of SDHB (Fig. 2a) . A deletion in SDHC exons 3 and 4 (patient 13) determined by MLPA analysis gave inconclusive qPCR results in this region with ratios of 0.75-0.85 (Fig. 2b) . The deletion breakpoint for patient 14 (deletion of SDHC exons 5 and 6) was narrowed to a 56 kb region downstream of SDHC (Fig. 2b) . Patient 15 carried a deletion of exon 4 of the SDHD gene that extended only slightly beyond the end of gene (Fig. 2c) . The breakpoints of patient 18, with a complete SDHD gene deletion, were narrowed by qPCR mapping to regions 2 kb upstream and 38 kb downstream of SDHD (Fig. 2c) . However, the downstream region was uncertain, due to borderline ratios of 0.75-0.85.
Breakpoint characterization
Following the further refinement of deleted regions by qPCR, we again applied the long-range PCR approach described above to identify exact breakpoints. Exact positions of the breakpoints could be determined in further three patients (patients 1, 5, 15). Of the four unresolved patients, three showed poor results suggesting low-quality DNA (patients 4, 13 and 14), and one could not be resolved due to exhaustion of available DNA (patient 18). All results are listed in Table 2 , which also provides information on neighboring genes affected by deletions. We have included schematic figures of all deletions and the location of the breakpoints identified in SDHB (Fig. S1), SDHC (Fig. S2) , and SDHD carriers ( Fig. S3) . Of the 16 deletions, 13 were simple deletions and 3 were deletions-insertions, including a 17 bp insertion (patient 8), a 6 bp insertion (patient 9), and an insertion of 133 bp in patient 20 that was identified as an AluS repeat. We also analyzed the breakpoint regions using Repbase (22) to determine whether Alu-Alu recombination is an underlying mechanism driving deletion in the SDH genes. Single deletion breakpoints were located in Alu repeats (patients 5, 7, 15) or in a mammalian long terminal repeat (LTR)-transposon 1 (MLT1) element (patients 11, 12) in the SDHD and SDHC genes providing no evidence for an influence of repeat sequences. Evidence for Alu-Alu recombination-mediated deletion was found for four SDHB gene deletions (patients 1, 3, 6, 7) .
Proximal genes
Several of the identified SDH gene deletions also affected neighboring genes. Patient 1 showed a deletion in the SDHB promoter together with exon 1 that also extended to include exons 2-16 of PADI2 (Peptidyl Arginine Deiminase 2) upstream of SDHB. In addition to complete gene deletion of SDHB in patient 5, upstream of SDHB exons 11-16 of PADI2 were lost and downstream the MFAP2 (Microfibrillar-Associated Protein 2) and ATP13A2 (PARK9) genes were entirely deleted. Mutations in ATP13A2/PARK9 have been linked to genetic forms of early onset Parkinsonism (23) . Patients 11 and 12 showed, in addition to deletion of SDHC exons 4-6, complete deletion of CFAP126 (Cilia And Flagella Associated Protein 126) ( Table 2 ). Complete gene deletion of TIMM8B (Mitochondrial import inner membrane translocase subunit Tim8 B) upstream of SDHD was found in patient 16. Patient 17 also showed deletion of the entire TIMM8B gene, in addition to partial deletion of C11orf57, upstream of SDHD.
Discussion
In this study, we characterized germline deletions of the SDH genes and flanking genes, identifying precise deletion breakpoints in 16 patients and deletions of up to 104 kb in size. The average size of a deletion was 23 kb. This study underlines the fact that clinically relevant deletions may encompass neighboring genes, with the potential to modify phenotype. Six of the deletions affected genes proximal to SDH. Deletions affecting neighboring genes may influence phenotypes, as apparent in the case of the VHL gene in which deletion of the actin regulator gene BRK1 together with the VHL gene reduces risk for renal cell carcinoma, kidney cysts and retinal angiomas (19, 24, 25) . Patient 1, with a deletion of the SDHB gene promoter and exon 1, also showed a deletion of exons 2-16 of PADI2. PAD enzymes convert protein arginine to citrulline, and citrullination has been associated with autoimmune responses such as those seen in rheumatoid arthritis (RA) (26) . Certain polymorphisms of the PADI2 gene are also associated with RA (27) . No additional phenotype is currently recognized in patient 1. In addition to complete gene deletion of SDHB, patient 5 was also affected by deletion of exons 11-16 of PADI2 and complete deletion of the genes MFAP2 and ATP13A2 (PARK9). MFAP2 is an antigen of elastin-associated microfibrils and may affect hematopoiesis (28) . Mfap2 −/− mice show bone abnormalities, hematopoietic changes, increased fat deposition, diabetes, compromised wound repair, and bleeding diathesis (29) . However, no human mutations in MFAP2 are currently known and heterozygous deletion of MFAP2 in this patient did not lead to an additional phenotype. ATP13A2 (PARK9) is involved in the pathogenesis of movement disorders and a heterozygous ATP13A2 gene frameshift mutation has been reported to cause juvenile Parkinsonism, a disease with an onset under 21 years of age (23) . Patient 5 had complete loss of one ATP13A2 allele, but no additional clinical features associated with Parkinsonism. A large ATP13A2 deletion has never been reported before in the literature. This deletion may not result in a phenotype because it currently appears that mutations with a relatively mild structural effect result in misfolded proteins that are the actual cause of symptoms, probably acting as dominant negative proteins (30) . If this patient had a Parkinson-like phenotype it would be the very first report of such a pathogenic mutation in this disease, and would require a re-think of pathogenic mechanisms.
Two patients with a deletion in exons 4-6 of SDHC (patient 11 and 12) also showed complete deletion of the CFAP126 gene. This gene might play a role in Charcot-Marie-Tooth disease, however no mutations in CFAP126 have been reported to date. In two other patients, genes proximal to SDHD were also affected by the deletion of TIMM8B (patients 16 and 17) and C11orf57 (patient 17). Little is known about the function of these genes but heterozygous deletions are not known to result in an additional phenotype (13) . Although we did not observe any clinical repercussions that can be attributed to deletions in these neighboring genes, some patients may be too young for a full phenotype to be manifested.
Of the 32 sequenced breakpoints, 13 (40%) were located in repeats, of which 11 (34% of total) were Alu elements. Most breakpoints located in Alu elements were identified in SDHB-related cases (10/18, 55%). In four SDHB-related cases there was evidence for Alu-Alu recombination-mediated deletion and analysis of the genomic structure of the SDHB gene revealed a high density of Alu repeats (44 elements that represent 31% of the sequence). A high density of Alu elements is likely to contribute to homologous Alu-mediated recombination, as shown for VHL mutant PCCs where most large VHL gene deletions are caused by recombination events driven by Alu repeat sequences (19) . The VHL locus sequence shows a very high Alu density of 49%, this may predispose the VHL gene to a high frequency of Alu-mediated deletions, in contrast to the SDH genes (mean Alu density of 29%). Our results suggest that Alu-mediated recombination does not play a major role in the deletion of SDH genes, since only 34% of all SDH deletions were located in Alu elements compared to 90% of VHL deletions (19) . This study also illustrates the practicality of a long-range 'chromosome walking' PCR strategy in the rapid and efficient mapping of deletion breakpoints. Although large deletions may represent up to 10% of all SDHx mutations, on a per center basis they are relatively rare and most centers will find few large deletions. At this point further mapping becomes problematic in terms of return on time invested. On the one hand, benefits of precise breakpoint mapping include exact identification of a variant, which facilitates family studies and the identification of founder mutations. The sequence-related mechanisms underlying large deletions can only be elucidated by breakpoint mapping. Furthermore, as so few deletions have been mapped in detail, we currently know little about possible additional phenotypes or phenotypic modification. On the other hand, drawbacks include the time required to map breakpoints, the expense and relative technical complexity of typical first-line methods such as qPCR, and the uncertainty surrounding the relevance and meaning of results. Our experience in this study suggests that any lab with a basic competence in molecular biology could rapidly map the majority of gene deletion breakpoints using standard equipment, and with personnel with limited experience. We suggest that while all deletions could be considered targets for long-range 'chromosome walking' PCR, this technique is at its most efficient when used to tackle deletions that show retention of some part of a gene. In practical terms, using this technique to analyze more than 100 kb flanking either side of a gene yields diminishing returns and other approaches such as qPCR or microsatellite mapping should perhaps be considered. Limitations of the chromosome walking approach include the lack of a positive control in PCR reactions, the possibility of false negative findings due to primers that produce PCR deletion products too large for efficient amplification (>10-12 kb) and the numerous off-target PCR products produced when primers are not consumed in the amplification of bona fide products.
In several cases, we used qPCR for further mapping of large deletions in the SDH genes. When successful, upstream or downstream gene regions can be very rapidly narrowed. However, this approach is relatively costly, time-consuming, difficult to interpret, and requires close supervision of inexperienced personnel. Our results were not always conclusive, possibly due to the variable quality of certain DNA samples, the inexperience of staff and to the intrinsically wider variability of this quantitative technique. As newer technologies, such as digital PCR, targeted arrays, targeted panel sequencing, and next-generation sequencing, are increasingly being used for routine clinical screening, and the costs for genome sequencing decreases, these techniques could be used in the future to detect copy-number changes (31) .
In conclusion, we identified 15 novel deletions, increasing the number of reported SDHx deletions to 46. The majority of deletions found in this study fell within the reach of our 'chromosome walking' approach. In several cases the initial characterization and confirmation of a deletion could be completed in a single long-range PCR experiment, followed directly by Sanger sequencing using the same primers. We hope that this method will provide a low threshold approach for labs facing the dilemma of whether to invest time and resources in the full characterization of deletions. Only by fully characterizing deletions and monitoring patients for possible additional phenotypes can we determine whether specific SDHx deletions and/or loss of neighboring genes have phenotypic consequences. Improved understanding of the function of deleted neighboring genes may allow new insights into subtle clinical effects.
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